US Analyst Reports on Immuron Products and R&D Pipeline
Released
Released
Announcement PDF
US Analyst Initiation Report on Immuron
3 February 2016, Melbourne, Australia: Immuron Limited (ASX:IMC) wishes to advise investors that
US-based equities company SeeThruEquity LLC, has released a research report on the entire Company, its
products and Research & Development programs and pipeline.
A copy of the SeeThruEquity’s Analyst Report can be viewed on the Immuron Company website at
http://immuron.com/investor-centre/analyst-reports/ or on the US Yahoo Finance website.
SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and
Zack's. The report will also be available on these platforms. The firm also contributes its estimates to
Thomson Estimates, the leading estimates platform on Wall Street.
Company Contact:
Thomas Liquard
Chief Executive Officer
AUS Ph: +61 (0)3 9824 5254
thomasliquard@immuron.com
Immuron US Investor Relations:
Jon Cunningham
RedChip Companies, Inc.
US Ph: +1 (407) 644 4256, (ext. 107)
jon@redchip.com
About SeeThruEquity LLC:
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market
capitalization. The research is not paid for and is unbiased. They do not conduct any investment banking or commission based
business. They are approved to contribute our research to Thomson Reuters One (First Call), CapitalIQ, FactSet, and Zacks and
distribute their research to our database of opt-in investors. They also contribute their estimates to Thomson Estimates, the
leading estimates platform on Wall Street.
SeeThurEquity started in March 2011 and since then, they have initiated coverage on numerous NYSE, NASDAQ, TSX, and OTC
companies in a variety of industries including technology, health care, consumer, energy and special situations and have hosted
several investor conferences in New York City.
For more information visit: http://www.seethruequity.com
About Immuron:
Immuron Ltd (ASX: IMC; OTCQB: IMROY) is a microbiome company focused on developing and commercialising oral
immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that
enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention
of travellers’ diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products
together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently
under development, will meet a large unmet need in the market.
For more information visit: http://www.immuron.com/
Suite 1, 1233 High Street
Armadale, Victoria
AUSTRALIA
3143
www.immuron.com
ABN: 80 063 114 045
Phone:
+ 61 (0)3 9824 5254
Facsimile: + 61 (0)3 9822 7735
Forward-Looking Statements:
Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and
projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are
intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable
assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties
inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed
or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which
the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking
statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any
appropriate regulatory authority.
Page 2 of 2
Share your feedback
Discover